Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature emphasized perioperative mental-health and safety interventions, implementation fidelity for enhanced recovery, and anesthesia pharmacogenetics. A large multicenter RCT found intraoperative esketamine improves short‑term remission of depressive symptoms after major surgery. Implementation research in pediatrics showed enhanced recovery benefits depend on high-fidelity delivery, and mechanistic genetic studies identified a mitochondrial ND4 variant that confe
Summary
This week’s anesthesiology literature emphasized perioperative mental-health and safety interventions, implementation fidelity for enhanced recovery, and anesthesia pharmacogenetics. A large multicenter RCT found intraoperative esketamine improves short‑term remission of depressive symptoms after major surgery. Implementation research in pediatrics showed enhanced recovery benefits depend on high-fidelity delivery, and mechanistic genetic studies identified a mitochondrial ND4 variant that confers sevoflurane vulnerability, with immediate implications for ancestry‑informed screening.
Selected Articles
1. Effect of intraoperative esketamine on moderate-to-severe depressive symptoms in major surgery patients: a randomized clinical trial.
Multicenter double‑blind RCT (n=435) showed intraoperative esketamine significantly increased remission of moderate‑to‑severe depressive symptoms at postoperative day 3 (28.3% vs 11.3%; OR 3.12) without changing acute pain; dissociative effects require monitoring.
Impact: Addresses a common, underrecognized perioperative problem with a pragmatic intraoperative intervention that produces rapid psychiatric benefit and is directly translatable to practice.
Clinical Implications: Consider structured screening for perioperative depressive symptoms and, where appropriate, intraoperative esketamine with postoperative psychiatric monitoring; weigh dissociation risk and integrate into multimodal recovery pathways.
Key Findings
- Esketamine increased 3‑day remission (28.3% vs 11.3%; OR 3.12).
- No difference in acute postoperative pain between groups.
- Dissociative/psychotomimetic symptoms were more common and require monitoring.
2. Implementation and Effectiveness of an Enhanced Recovery Protocol for Children Undergoing Surgery: The ENRICH-US Stepped-Wedge Cluster-Randomized Trial.
An 18‑site stepped‑wedge cluster RCT (n=597) found no phase‑level LOS reduction overall, but high patient‑level fidelity (≥13 ERP elements) was associated with shorter LOS (−1.14 days) and fewer complications (aOR 0.48), demonstrating that implementation quality mediates ERP effectiveness.
Impact: Shifts the focus from whether ERPs work to how they must be implemented; provides rigorous multisite evidence linking fidelity metrics to clinical benefit in pediatrics.
Clinical Implications: Prioritize fidelity‑focused implementation (order‑set integration, learning collaboratives, fidelity dashboards) when deploying pediatric ERPs; measure core element delivery to realize LOS and complication reductions.
Key Findings
- No overall LOS reduction by phase, but decreased inpatient opioid use and faster time to diet were seen.
- Patients receiving ≥13 ERP elements had shorter LOS (−1.14 days) and fewer complications (aOR 0.48).
- Site integration into order sets and culture correlated with higher fidelity.
3. Effects of a Mitochondrial Genetic Variant on Sevoflurane Hypersensitivity.
Case series with mechanistic validation identified the mtDNA m.11232T>C (ND4 L158P) variant in patients with severe perioperative neurologic deterioration; patient‑derived cell models showed sevoflurane selectively suppressed complex I–dependent respiration in variant cells whereas propofol did not, implicating mitochondria‑linked pharmacogenetic risk.
Impact: Provides a concrete, mechanistically validated genetic signal that can immediately inform ancestry‑informed perioperative screening and agent selection to prevent catastrophic neurologic events.
Clinical Implications: Consider targeted mtDNA screening or altered anesthetic plans (favoring intravenous agents) for patients from high‑risk maternal lineages or with suggestive family history; increase postoperative neurologic vigilance when inhalational agents are used.
Key Findings
- All affected patients shared m.11232T>C (ND4 L158P) mtDNA variant.
- Sevoflurane exposure suppressed complex I–dependent mitochondrial respiration in variant‑harboring cells; propofol did not show this differential effect.
- Some individuals tolerated intravenous anesthesia without adverse events, implicating inhalational agents in risk expression.